FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Once every four weeks maintenance dosing may be easier for patients and care partners ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late... ByInvesting.com • Mar 11, 2025 Biogen director Stephen Sherwin ...

The phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo in adult kidney transplant recipients diagnosed with late antibody-mediated ...

I Mab Aktie und aktueller Aktienkurs: Bleiben Sie über den aktuellen Aktienkurs von I Mab (IMAB) stets informiert - direkt auf dieser Seite. Behalten Sie den vor- und nachbörslichen Handel der ...

US-based biotechnology company Biogen has begun dosing in the Phase III TRANSCEND trial to assess felzartamab in adult kidney transplant recipients with late antibody-mediated rejection (AMR).

Felzartamab is still an investigational drug that has not yet received regulatory approval, which poses a risk for investors and stakeholders regarding its eventual market success. The need for a ...

BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay” or the "Company”), a global leader in advanced noninvasive neurostimulation ...

The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo in adult kidney transplant recipients diagnosed with late antibody-mediated ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMR AMR is a leading cause of kidney transplant loss, with ...

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients Global Phase 3 TRANSCEND study will evaluate the efficacy ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMR AMR is a leading cause of kidney transplant loss, with ...

Enttäuschende Zahlen drücken die Aktie des Biotech-Unternehmens Biogen auf den tiefsten Stand seit mehr als einer Dekade. Vor allem das Multiple-Sklerose-Business und die Erlöse mit dem ...